Last mentioned: Feb 21, 2026
Valuation Period
Expected timeframe for determining the fair market value of the equity investment.
Option Exercised
PsyLabs officially triggers the put option, requiring an equity investment from PBM.
Put Option Exercised
PsyLabs Ltd. formally exercises its rights under the Put Option Agreement with Psyence BioMed.
Strategic Investment Announced
Psyence BioMed announces it will make an equity investment in PsyLabs at fair market value.
Put Option Established
Psyence BioMed and PsyLabs enter into a strategic put option agreement.
Psyence Biomedical Ltd. (Nasdaq: PBM) has announced a strategic equity investment in PsyLabs Ltd. after the manufacturer exercised its rights under a previously established put option agreement. This move strengthens the relationship between the biopharmaceutical developer and its primary supplier of nature-derived psychedelic compounds.
Psyence Biomedical Ltd. (Nasdaq: PBM) has confirmed a strategic equity investment in PsyLabs following the exercise of a previously established put option. This move deepens the integration between the biopharmaceutical developer and its primary manufacturer of pharmaceutical-grade psychedelic compounds.